AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

Core Viewpoint - AbbVie Inc. reported strong second-quarter 2025 earnings, exceeding revenue and EPS expectations, which has positively impacted its stock price [1][6]. Financial Performance - AbbVie achieved global net revenue of $15.42 billion, surpassing the expected $14.93 billion [1]. - The earnings per share (EPS) was reported at $2.97, exceeding the forecast of $2.91 by 2% [1]. - Humira's net revenues were $1.18 billion, reflecting a year-over-year decline of 58.1% [5]. - Skyrizi generated net revenues of $4.42 billion, a 61.8% increase year-over-year, while Rinvoq reported $2.02 billion, a 41.8% increase [5]. - The overall immunology portfolio contributed $7.63 billion to global net revenues, accounting for nearly 50% of the total quarterly revenue, which was up 6.8% year-over-year [5]. Guidance and Outlook - AbbVie raised its full-year EPS guidance to a range of $11.88 to $12.08, higher than the previous guidance of $11.67 to $11.87 [6]. - The company’s positive outlook comes despite potential impacts from a new 15% tariff on EU-produced pharmaceuticals entering the U.S. [7]. Stock Performance and Analyst Ratings - AbbVie stock is currently priced at $195.40, with a 12-month price target of $211.29, indicating an 8.80% upside [2][8]. - The stock has a moderate buy rating among analysts, with a consensus price target that may increase following the strong earnings report [12][13]. Strategic Moves - AbbVie is actively pursuing growth through acquisitions, including a $2.1 billion acquisition of Capstan Therapeutics, which will enhance its immunology pipeline [9][10]. - The company is also in talks to acquire Gilgamesh Pharmaceuticals for around $1 billion, focusing on next-generation psychedelic treatments [11].